Breaking Finance News

A report released today by H.C. Wainwright about Acceleron Pharma (NDAQ:XLRN) bumps the target price to $57.00

Yesterday Acceleron Pharma (NDAQ:XLRN) traded -1.85% lower at $38.92. The company’s 50-day moving average is $37.48 and its 200-day moving average is $32.05. The last closing price is up 20.95% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 269,709 shares of the stock were exchanged, down from an average trading volume of 426,994

H.C. Wainwright increased the stock price target of Acceleron Pharma (NDAQ:XLRN) to $57.00 reporting a potential upside of 0.46%.

Previously on 09/15/2017, RBC Capital Markets reported on Acceleron Pharma (NDAQ:XLRN) raised the target price from $0.00 to $44.00. At the time, this indicated a possible upside of 0.11%.

See Chart Below

Acceleron Pharma (NDAQ:XLRN)

Acceleron Pharma has a 52 week low of $23.07 and a 52 week high of $41.69 The company’s market cap is currently $0.

Also covering Acceleron Pharma's price target, a total of 9 analysts have released a report on Acceleron Pharma. The 12-month target is $47.33 with four equity analysts rating the company a strong buy, 4 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Acceleron Pharma (NDAQ:XLRN)

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.